zenocutuzumab
Merus
['cross tumor']
#asco22 data from dr. tell us #nrg1 fusions occur at a low incidence across tumor types and we know from the enrgy1 registry (project led by drs. , , and myself, see ), outcomes with standard therapy are poor. 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him